UBS skeptical of Novo Nordisk's sky-high market valuation
A UBS analyst believes increased competition on the obesity market combined with high prices will lead to Novo’s rival, Eli Lilly, taking a bigger slice of the pie.
by marketwire, translated by daniel pedersen
Global bank UBS, which is based in Switzerland, is skeptical about the market’s high valuation of Novo Nordisk, and is predicting the future will bring increasing resistance against high prices for obesity treatments, one such being the Danish drugmaker’s product, Wegovy (semaglutide).
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Novo Nordisk's semaglutide shows potential against addiction
For subscribers
